

Triple dual therapy significantly improves lung function, quality of life in COPD patients

October 4 2018

The InforMing the PATHway of COPD Treatment (IMPACT) study was conducted to assess the benefits of triple versus dual therapy in patients with COPD. In a study at *CHEST*, researchers found that regardless of baseline reversibility, the usage of triple dual therapies significantly reduced the annual rate and moderate-to-severe and severe exacerbations, improved lung function and overall quality of life in patients.

The randomized, double-blind, parallel-group, global study was conducted in 10,355 symptomatic [patients](#) with COPD with a history of moderate-to-severe exacerbations over a 52-week period. During the screening, patient was defined as reversible through differences shown between their pre- and post-albuterol assessments of forced expiratory volume in 1 second (FEV1) of ≥ 12 percent and ≥ 200 mL. Researchers also assessed the effect of baseline reversibility on treatment response with [fluticasone furoate](#) (FF)/umeclidinium (UMEC)/vilanterol (VI) and with FF/VI and UMEC/VI. The [lung function](#) and quality of life (QoL) of patients were measured by St George Respiratory Questionnaire (SGRQ) and observed for FF/UMEC/VI over UMEC/VI independent of reversibility status at screening.

During screening, 18 percent of patients demonstrated reversibility. In both reversible and nonreversible patients, there was a statistically significant reduction in the rate of moderate and severe exacerbations

with FF/UMEC/VI as compared to UMEC/VI. They also found a reduction in the risk of having a moderate/severe [exacerbation](#) and the risk of having a severe exacerbation in both groups of patients. Quality of life was also improved in both reversible and non-reversible patients.

More information: ROBERT WISE et al, TREATMENT EFFECTS OF FF/UMEC/VI VS FF/VI AND UMEC/VI IN REVERSIBLE AND NONREVERSIBLE COPD PATIENTS: ANALYSES OF THE IMPACT STUDY, *Chest* (2018). [DOI: 10.1016/j.chest.2018.08.662](https://doi.org/10.1016/j.chest.2018.08.662)

Provided by American College of Chest Physicians

Citation: Triple dual therapy significantly improves lung function, quality of life in COPD patients (2018, October 4) retrieved 27 April 2024 from <https://medicalxpress.com/news/2018-10-triple-dual-therapy-significantly-lung.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
--